Journalartikel
Autorenliste: Keranov, Stanislav; Widmann, Laila; Jafari, Leili; Liebetrau, Christoph; Keller, Till; Troidl, Christian; Kriechbaum, Steffen; Voss, Sandra; Bauer, Pascal; Richter, Manuel J.; Tello, Khodr; Gall, Henning; Ghofrani, Hossein A.; Wiedenroth, Christoph B.; Guth, Stefan; Seeger, Werner; Hamm, Christian W.; Nef, Holger; Dorr, Oliver
Jahr der Veröffentlichung: 2022
Seiten: 1193-1207
Zeitschrift: Biomarkers in Medicine
Bandnummer: 16
Heftnummer: 17
ISSN: 1752-0363
eISSN: 1752-0371
DOI Link: https://doi.org/10.2217/bmm-2022-0395
Verlag: Taylor and Francis
Abstract:
Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 >1363 pg/ml and sST2 >38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.
Zitierstile
Harvard-Zitierstil: Keranov, S., Widmann, L., Jafari, L., Liebetrau, C., Keller, T., Troidl, C., et al. (2022) GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension, Biomarkers in Medicine, 16(17), pp. 1193-1207. https://doi.org/10.2217/bmm-2022-0395
APA-Zitierstil: Keranov, S., Widmann, L., Jafari, L., Liebetrau, C., Keller, T., Troidl, C., Kriechbaum, S., Voss, S., Bauer, P., Richter, M., Tello, K., Gall, H., Ghofrani, H., Wiedenroth, C., Guth, S., Seeger, W., Hamm, C., Nef, H., & Dorr, O. (2022). GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension. Biomarkers in Medicine. 16(17), 1193-1207. https://doi.org/10.2217/bmm-2022-0395
Schlagwörter
biomolecules; CHRONIC HEART-FAILURE; Chronic thromboembolic pulmonary hypertension; FIBROSIS; Galectin-3; GROWTH-DIFFERENTIATION FACTOR-15; idiopathic pulmonary arterial hypertension; Left ventricular hypertrophy; PROGNOSTIC VALUE; right ventricular maladaptation; Right ventricular-pulmonary arterial coupling; right ventricular remodeling
